Inflammation, apoptosis, and BPH: What is the evidence?

被引:19
作者
Novara, G
Galfano, A
Boscolo-Berto, R
Ficarra, V
Navarrete, RV
Artibani, W
机构
[1] Univ Padua, Dept Oncol & Surg Sci, Urol Clin, I-35128 Padua, Italy
[2] Univ Verona, Dept Urol, I-37100 Verona, Italy
[3] Univ Autonoma Madrid, Fdn Jimenez Diaz, Catedra & Serv Urol, Madrid, Spain
关键词
apoptosis; alpha-blockers; benign prostate hyperplasia; caspase; doxazosin; dutasteride; finasteride; inflammation; inhibitors; phytotherapeutic agents; 5-alpha-reductase; Serenoa repens; terazosin;
D O I
10.1016/j.eursup.2006.02.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men but its aetiology is far from being completely understood. Methods: Data were identified by searching MEDLINE from which 134 records were identified. Full texts were reviewed by to select the most relevant studies. In addition, other significant texts cited in the reference lists of the selected papers were considered. Results: Based on the role played in several models of human pathology, inflammation and apoptosis have been extensively investigated in the last decade. Inflammation is the basic process whereby tissues of the body respond to injury. Detection of injury or the presence of invaders in the tissue leads to a relatively circumscribed set of responses that removes the damaged structures and cells, kills and clears the invaders, and promotes cell and matrix replacement and repair. The role of inflammation in prostate pathologies is suggested by the presence of several kinds of inflammatory cells within the normal gland, as well as in patients with BPH and prostate cancer. Apoptosis (or programmed cell death) refers to the death of cells, which occurs as a normal and controlled part of the growth of an organism. Apoptosis is currently considered a genetically encoded, ubiquitous pathway, enabling cells to undergo highly regulated cell death in response to specific signalling, which have been largely investigated, as well as its intracellular effectors. Both inflammation and apoptosis are of major interest in understanding the aetiology of BPH, as well as the action mechanism of the drugs currently used and, most importantly, the development of new, more efficacious molecules. Conclusion: This review summarises the available evidence concerning the role of inflammation and apoptosis in BPH pathogenesis and treatment. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:401 / 409
页数:9
相关论文
共 64 条
[31]   Doxazosin and terazosin suppress prostate growth by inducing apoptosis: Clinical significance [J].
Kyprianou, N .
JOURNAL OF UROLOGY, 2003, 169 (04) :1520-1525
[32]   Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia [J].
Kyprianou, N ;
Litvak, JP ;
Borkowski, A ;
Alexander, R ;
Jacobs, SC .
JOURNAL OF UROLOGY, 1998, 159 (06) :1810-1815
[33]   Apoptotic versus proliferative activities in human benign prostatic hyperplasia [J].
Kyprianou, N ;
Tu, HC ;
Jacobs, SC .
HUMAN PATHOLOGY, 1996, 27 (07) :668-675
[34]   Dutasteride, the dual 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line [J].
Lazier, CB ;
Thomas, LN ;
Douglas, RC ;
Vessey, JP ;
Rittmaster, RS .
PROSTATE, 2004, 58 (02) :130-144
[35]  
LEE C, 2001, 5 INT CONS BEN PROST, P81
[36]   Molecular and cellular pathogenesis of benign prostatic hyperplasia [J].
Lee, KL ;
Peehl, DM .
JOURNAL OF UROLOGY, 2004, 172 (05) :1784-1791
[37]   EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) [J].
Madersbacher, S ;
Alivizatos, G ;
Nordling, J ;
Sanz, CR ;
Emberton, M ;
de la Rosette, JJMCH .
EUROPEAN UROLOGY, 2004, 46 (05) :547-554
[38]   Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7 [J].
Marcelli, M ;
Shao, TC ;
Li, XY ;
Yin, H ;
Marani, M ;
Denner, L ;
Teng, B ;
Cunningham, GR .
JOURNAL OF UROLOGY, 2000, 164 (02) :518-525
[39]   The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia [J].
McConnell, JD ;
Roehrborn, CG ;
Bautista, OM ;
Andriole, GL ;
Dixon, CM ;
Kusek, JW ;
Lepor, H ;
McVary, KT ;
Nyberg, LM ;
Clarke, HS ;
Crawford, ED ;
Diokno, A ;
Foley, JP ;
Foster, HE ;
Jacobs, SC ;
Kaplan, SA ;
Kreder, KJ ;
Lieber, MM ;
Lucia, MS ;
Miller, GJ ;
Menon, M ;
Milam, DF ;
Ramsdell, JW ;
Schenkman, NS ;
Slawin, KM ;
Smith, JA ;
Kusek, JW ;
Nyberg, LM ;
Briggs, JP ;
McConnell, JD ;
Crawford, ED ;
Homan, K ;
Donohue, R ;
Parker, D ;
Easterday, K ;
Robertson, K ;
Kaplan, S ;
Wentland, M ;
Hardy, L ;
Roehrborn, C ;
Ahrens, A ;
McConnell, J ;
Hall, D ;
Cutts, D ;
Carter, S ;
Waldrep, K ;
Schenkman, N ;
Sanetrik, K ;
Sihelnik, S ;
Zorn, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2387-2398
[40]  
MCNEAL J, 1990, UROL CLIN N AM, V17, P477